My interest for research started in 2005 during my undergraduate studies at the Pharmacy School, which is part of the University of Extremo Sul Catarinense in Brazil. From 2005 to 2009, I carried out some research at an ethnopharmacology laboratory, which, in turn led me to learn the basics of neuropsychopharmacology and behavioral neuroscience and to be instigated by this field of study.

In August, 2009, I started my masters studies at Prof. Dr. Sâmia Joca's laboratory at the Department of Pharmacology of the Medicine School of Ribeirão Preto, University of São Paulo, where I could dedicate myself to the study of the neurobiology of depression and stress, mostly focused on the role of the glutamatergic and nitrergic system over behavioral control. In August, 2011, right after I earned my master's degree, I continued my studies at Dr. Sâmias lab as a PhD student. Thus, from 2011 to 2015, I researched the mechanisms of action of new fast acting antidepressants, and how these drugs interacted with neurothrophic pathways into the medial prefrontal cortex. Through this period, both my master's and PhD studies allowed me to participate in different national and international conferences, at which I was awarded twice for good poster presentations. In addition, being   a part of an engaging collaboration work during my PhD, also allowed me to study and publish interesting data on the role of the purinergic system in the neurobiology of depression.

 In 2012, during the 28th CINP World Congress in Stockholm, Dr. Sâmia introduced me to Professor Dr. Gregers Wegener from Aarhus University, which led to productive scientific discussions. Dr. Gregers, then, invited me to come to his lab and so, in 2013 I visited Aarhus for the first time, where I stayed for a 4 month period to run some collaboration experiments for my PhD studies. 

In 2014, when I was about to finish my PhD, Dr. Gregers invited me to return to his lab as a postdoctoral research fellow, which I promptly accepted. Therefore, since May, 2015 I have been a researcher at the Translational Neuropsychiatry Unit, Department of Clinical Medicine of Aarhus University, developing different studies about treatment-resistant depression and new ways to bypass this problem. To this end, I have been mostly interested on the role of glutamatergic, nitrergic and endocannabinoid systems as targets to the development of new and better drugs to the pharmacological treatment of major depression.